What Changes to FDA and CBER Mean for the Future of CGT with Daniela Drago

We love to hear from our listeners. Send us a message. This is Episode 4 of "FDA Fridays," a special series from Cell & Gene: The Podcast, Chief Editor Erin Harris speaks with regulatory affairs expert Daniela Drago, Partner, NDA Partners, about how shifting FDA and CBER priorities under the current administration could influence the trajectory of cell and gene therapy development. From the impact of leadership changes and evolving policy directives to the role of funding allocations and public health priorities, Drago sheds light on what CGT developers and sponsors should be watching most closely. She explores regulatory modernization trends, including digital health integration, real-world evidence, and decentralized trial models, and offers practical guidance on how companies can best prepare for potential regulatory shifts while maintaining alignment with FDA expectations for safety, efficacy, and manufacturing rigor.

You can listen to What Changes to FDA and CBER Mean for the Future of CGT with Daniela Drago online on Radio and Podcast. Open the player on this page to stream the available audio.

What Changes to FDA and CBER Mean for the Future of CGT with Daniela Drago is an episode from Cell & Gene: The Podcast by Erin Harris.

This episode is 23:15 long.

This episode was published on Aug 29, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Cell & Gene: The Podcast when more episodes are available from the podcast feed.